# US 2014/0155576 A1 · F11 receptor (f11r) antagonists as therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155576 A1
- Document ID: US20140155576A1
- Status: Published application
- Kind: A1
- Application number: 14/052,147
- Filed: 2013-10-11
- Published: 2014-06-05
- Earliest claimed: 2003-01-03
- Assignees: The Research Foundation for The State University of New York
- Inventors: Elizabeth Kornecki; Anna Babinska; Yigal H. Ehrlich
- Web page: https://patentgrep.com/patent/US20140155576A1

## CPC

- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 5/10: Tetrapeptides
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal.

## Claims

### Claim 1

A compound comprising a peptidomimetic which interacts sterically with the binding site of a F11R molecule, wherein the peptidomimetic has a sequence selected from the group consisting of dKSVTdREDTGTYTC-CONH2, KSVTdREDTGTYTC-CONH2, SVTdREDTGTYTC-CONH2, VTdREDTGTYTC-CONH2, TdREDTGTYTC-CONH2, dREDTGTYTC-CONH2, REDTGTYTC-CONH2, EDTGTYTC-CONH2, DTGTYTC-CONH2, TGTYTC-CONH2, GTYTC-CONH2, dKSVTdREDTGTYTC, dKSVTdREDTGTYT, dKSVTdREDTGTY, dKSVTdREDTGT, dKSVTdREDTG, dKSVTdREDT, dKSVTdRED, dKSVTdRE, dKSVTdR, dKSVTd and dKSVT.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the peptidomimetic has a sequence selected from the group consisting of VTVHSSEPEVRIPENNPVKLSC, TVHSSEPEVRIPENNPVKLSC, VHSSEPEVRIPENNPVKLSC, HSSEPEVRIPENNPVKLSC, SSEPEVRIPENNPVKLSC, SEPEVRIPENNPVKLSC, EPEVRIPENNPVKLSC, PEVRIPENNPVKLSC, EVRIPENNPVKLSC, VRIPENNPVKLSC, RIPENNPVKLSC, IPENNPVKLSC, PENNPVKLSC, ENNPVKLSC, NNPVKLSC, NPVKLSC, PVKLSC, VKLSC, SVTVHSSEPEVRIPENNPVKLS, SVTVHSSEPEVRIPENNPVKL, SVTVHSSEPEVRIPENNPVK, SVTVHSSEPEVRIPENNPV, SVTVHSSEPEVRIPENNP, SVTVHSSEPEVRIPENN, SVT VHSSEPEVRIPEN, SVTVHSSEPEVRIPE, SVTVHSSEPEVRIP, SVTVHSSEPEVRI, SVTVHSSEPEVR, SVTVHSSEPEV, SVTVHSSEPE, SVTVHSSEP, SVTVHSSE, SVTVHSSE, SVTVHSS, SVTVHS and SVTVH.